guide evaluation of children with suspected mitochondrial liver disease. Data informing the evaluation guideline was supported by Medline searches of published English language literature and expert opinion from a committee of pediatric hepatologists and a mitochondrial metabolism specialist.
Mitochondrial respiratory chain defects can affect any tissue, with the most energydependent organs being most vulnerable. (1) In general, clinical manifestations include multisystem involvement such as brain, muscle, heart, or kidney, with acute or chronic liver dysfunction, sometimes in the presence of lactic acidosis, a biomarker of limited sensitivity. (2, 3) Heterogeneous clinical presentations can be explained by the fact that the mitochondrial quantity and function are uniquely influenced by both nuclear and mitochondria DNA (mtDNA) or by the fact that cells in various tissues can contain different mixtures of normal and abnormal mitochondrial genomes (heteroplasmy). Most mitochondrial proteins and enzymes are coded by nuclear genes with Mendelian inheritance, while some respiratory chain subunits, ribosomal and transfer RNAs are encoded by mitochondrial genes that are maternally inherited.(4) Mutations, deletions, or duplications in either of these classes can cause disease, and mutations in nuclear genes that control mitochondrial DNA replication, transcription, and translation may lead to mtDNA depletion syndrome or to a translational disorder. (5) (6) (7) The respiratory chain, consisting of 5 multimeric complexes (I-V) in the mitochondrial inner membrane, generates energy as ATP via electron transport and oxidative phosphorylation ( Figure 1 ). Defects in the respiratory chain enzymes or mitochondrial membrane transport proteins result in injury to energy-dependent organs, especially brain, retina, muscle, heart, and liver. (8) In addition, hepatic mitochondria oxidize fatty acids forming ketone bodies, an important source of energy for the brain in the fasting state. Fatty acid oxidation defects, an important group of primary bioenergetic defects, can present similarly with hepatopathy or encephalopathy, often with nonketotic hypoglycemia, acidosis and hyperammonemia, and are thus included in the differential diagnosis and should be simultaneously evaluated. (9) Establishing the diagnosis of primary mitochondrial bioenergetic defects in patients with liver disease requires a high index of suspicion in specific clinical scenarios. A tiered diagnostic evaluation is useful (Table 1) . Although mitochondrial hepatopathies are a heterogeneous group of disorders, there are several general laboratory investigations in blood and urine which can reveal an altered redox status suggestive of respiratory-chain defects (lactate:pyruvate molar ratios and ketone body ratios). Specific laboratory tests are considered in those with unique clinical presentations as well, and either tissue analysis or genotyping is used to identify the etiology. Other typically involved organ systems should be evaluated when mitochondrial hepatopathy is suspected ( Table 2) . Several important management issues should be addressed during this evaluation process. These guidelines outline the evaluation of the infant or child with suspected mitochondrial hepatopathy. Two summary tables (Table 3 and 4) describing each genetic etiology follow; reference clinical laboratories for the genetic tests can be found on www.genetests.org
I. Clinical Scenarios Suggesting Possible Mitochondrial Liver Disease
Mitochondrial liver disease can present acutely in a child with no history of hepatic dysfunction, or with chronic liver and CNS disease. Fulminant or acute liver failure is one important presentation of mitochondrial disease.(10) Especially in a young child or in one with pre-existing or disproportionate central nervous system (CNS) involvement, mitochondrial disease is in the differential diagnosis of acute liver failure. Importantly, if liver transplant is being considered, careful attention must be paid to potential extrahepatic manifestations of mitochondrial dysfunction. Another clinical presentation is chronic liver disease, manifested by elevated aminotransferases, hepatomegaly, cholestasis, cirrhosis and especially steatohepatitis; these may be accompanied by other indicators of mitochondrial disease including hypoglycemia or lactic acidosis. Thirdly, liver disease accompanied by chronic neuromuscular disease or disease in other organ systems may be a sign of mitochondrial disease.
II. Tiered Diagnostic Evaluation
A wide array of tests which are useful in establishing the diagnosis of mitochondrial hepatopathies is available. These tests range from simple, inexpensive, easily available screening tests to very expensive widely ranging genetic studies. In the child who is suspected of having a mitochondrial disease, a tiered approach to diagnostic testing is recommended. Early screening tests (Tier 1) might provide clues to abnormalities in energy metabolism and results of these tests might guide subsequent confirmatory testing to establish a molecular diagnosis. Genotyping is available clinically for the more common mitochondrial diseases (Tier 2); the clinical scenario or results of screening tests can inform the choice of genetic tests. For example, a panel screening for specific gene mutations in DGUOK, POLG1, and MPV17 responsible for infantile liver failure with lactic acidosis and mitochondrial DNA depletion is readily available and might be useful early in evaluation (see Table 3 ). The diagnostic role of Next-Generation Sequencing (NGS), which is now allowing sequencing of more than 100 genes involved in mitochondrial diseases with a single blood test and at relatively low cost, (11) or even whole exome or genome sequencing, will become increasingly important and will eventually replace genotyping single genes or small panels of genes in Tier 2; however, the identification of multiple gene variants of uncertain significance will require detailed clinical and biochemical confirmation for interpretation. Tissue may also be needed to make a specific biochemical diagnosis, particularly if the liver is the major or sole affected organ (tier 3; Figure 2 ). Occasionally, diagnostic findings will only be revealed in liver tissue rather than in blood, muscle, or skin fibroblasts. When further clarification is needed, genotyping for less common diseasecausing genes may be required (Tier 4); however, the use of NGS earlier on in the evaluation process in the future (in Tier 2) may obviate the need for this step in the evaluation paradigm. At present, the diagnostic yield of NGS of all mitochondrial genes is high in patients with well characterized mitochondrial disease, in particular with biochemical evidence of mitochondrial enzymatic dysfunction (11), but is low in patients with only a clinical suspicion. (12) Biochemical studies evaluating the structure and function of mitochondrial subunits in the affected tissue can be performed as needed, specifically to determine if new genetic variants have a functional effect ( Figure 3 ). Thus, a combination of biochemical and molecular studies may be needed to confirm the pathologic nature of new gene variants to be described in the future. Table 1 below outlines a tiered approach to diagnostic evaluation.
The following Tables 3 and 4 catalog known mitochondrial hepatopathies and briefly describe the mutation, defect, clinical description, and diagnostic testing. The typical hepatic presentation, ranging from hepatic failure to cholestasis to steatohepatitis to cirrhosis is briefly outlined; neurologic symptoms and other systems involved are briefly reviewed and references are provided. The disorders are separated into those with a neonatal or infantile presentation (Table 3 ) and those with later or more chronic onset (Table 4 ). There is, however, overlap between these two, and new diseases and presentations are recognized frequently.
III. Evaluation for Disease in Other Organ Systems
As part of the evaluation for mitochondrial hepatopathies, a systematic approach also needs to be instituted to search for involvement of other affected organ systems ( Table 2 ). This takes on particular significance when liver failure occurs in a child with suspected mitochondrial disease, as the decision to consider liver transplantation is especially challenging. Because mitochondrial disease usually involves multiple organ systems and is generally progressive in other organs even following liver transplantation, there are many uncertainties regarding liver transplantation. Possible post-transplant appearance of new progressive symptoms in organs uninvolved prior to liver transplantation also needs to be considered. (43) (44) (45) (46) . Establishing criteria for liver transplantation in mitochondrial hepatopathies is beyond the scope of this report. However, in the evaluation for transplantation, meticulous evaluation for disease in other organ systems is paramount, especially since results of testing for specific disorders can be delayed by weeks. Evaluation of the central nervous system is critical. Besides a careful neurologic examination, MRI of the brain is done to evaluate for Leigh disease, cerebellar atrophy, leukodystrophy, and cerebral atrophy. MR spectroscopy can be especially helpful, but blood lactate >3 mmol/L may affect interpretation. Evaluation can also include EEG and CSF examination (see above). To evaluate for cardiomyopathy, EKG and echocardiogram should be done. A detailed ophthalmologic exam may reveal ophthalmoplegia in DGUOK deficiency, retinopathy in LCHAD or respiratory chain defects, corneal abrasions in MPV17, or optic atrophy in POLG disease. Serum electrolytes, serum and urine phosphorus and creatinine, urine amino acids, urinalysis, and urine protein are measured to evaluate renal function since abnormal tubular function may suggest a defect in BCS1L. Because diabetes and even adrenal insufficiency can be seen in mitochondrial disorders, HbA1c and morning cortisol level should be considered. Pancreatic insufficiency is seen in some mitochondrial diseases and may be detected by measuring fecal pancreatic elastase. Hearing screening should be performed.
IV. Management during Evaluation for Possible Mitochondrial Disease
The child with mitochondrial disease can be vulnerable to metabolic perturbations such as hypoglycemia or acidosis; close monitoring is important. It is important to discontinue or avoid medications that may exacerbate hepatopathy or impair mitochondrial function or mtDNA translation or transcription, including sodium valproate, tetracycline and macrolide antibiotics, reverse transcriptase inhibitors (particularly AZT), chloramphenicol, quinolones, and linezolid.(47) Use of Ringer's lactate intravenous solution should be avoided because the liver may not be able to metabolize lactate; propofol should be avoided during anesthesia or sedated procedures since the drug can interfere with mitochondrial function. (48) The goal is to maintain anabolism using a balanced intake of fat and carbohydrates with at least 75% of normal caloric intake while avoiding unbalanced intakes (e.g., glucose only at high intravenous rate) or fasting for >12 hours. (49) In patients with preexisting lactic acidosis, lactate levels should be monitored around procedures to avoid excessive lactic acidosis.
Conclusion
Mitochondrial disease can present from infancy to adulthood with varying degrees of hepatic and extrahepatic involvement. In the last decade, there has been a rapid expansion of newly recognized mitochondrial diseases and their molecular bases. Available technology to aid in diagnosis has improved substantially. Nonetheless, diagnosis of suspected mitochondrial disease in children is complicated; a systematic clinical, biochemical, and molecular approach can aid in making a timely, accurate, and cost-effective diagnosis. Coenzyme-Q levels in leukocytes, not serum (for CoQ deficiency; leukocyte levels correlate better with tissue coenzyme Q levels, whereas serum levels reflect nutritional status).
Quantitative serum methylmalonic acid (elevated in SUCLA and SUCLG1 deficiencies).
CSF analysis: Lactate and pyruvate (if blood lactate is normal but evidence of CNS involvement), amino acids (especially elevated CSF alanine), and protein concentration (note CSF protein can be elevated in POLG1 disease early on, even when lactate is normal).
Tier 2 Genotyping for More Common Genes
Most common with liver involvement: POLG1 (15, 16) , DGUOK (17) (18) (19) , MPV17 (20, 21) , SUCLG1 (22) , C10ORF2/Twinkle (23) , TRMU (see Tables 3 and 4 ). For recurrent acute liver failure: TRMU, ACAD9, CPTI, SUCLGI. (22, 26, 30, 31) Identification of TRMU mutations is urgent in infants with acute liver failure since these patients frequently recover without the need for transplantation. (31, 32) Note: Next Generation Sequencing (e.g., exome sequencing) will allow for simultaneous evaluation of panels of all nuclear genes encoding mitochondrial proteins and all mitochondrial DNA genes at considerably lower cost in the future, encompassing the above gene tests, and will eventually replace single gene sequencing. It is already available in some countries. 
If neuromuscular features suggest MELAS (Mitochondrial

Tier 3 Tissue Evaluation
